

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



Rilpivirine

Item No. 21559

CAS Registry No.: 500287-72-9

Formal Name: 4-[[4-[(1E)-2-cyanoethenyl]-

2,6-dimethylphenyl]amino]-2-

pyrimidinyl]amino]-benzonitrile

Synonyms: R278474, TMC278

MF: $C_{22}H_{18}N_6$ FW: 366.4 **Purity:** ≥98%

UV/Vis.: λ_{max} : 306 nm Supplied as: A crystalline solid

-20°C Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Rilpivirine is supplied as a crystalline solid. A stock solution may be made by dissolving the rilpivirine in the solvent of choice, which should be purged with an inert gas. Rilpivirine is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of rilpivirine in these solvents is approximately 0.2 and 0.3 mg/ml, respectively.

Rilpivirine is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, rilpivirine should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Rilpivirine has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits growth of wild-type HIV with an EC₅₀ value of 0.51 nM.¹ It is active against NNRTI-resistant HIV strains with EC₅₀ values less than 1 nM for L100I, K103N, V106A, G190A, and G190S mutants in vitro. Rilpivirine also reduces growth of greater than 80% of 1,500 NNRTI-resistant clinical isolates (EC_{50} S = <10 nM), including strains containing up to eight resistance mutations. In vivo, rilpivirine, when used in combination with cabotegravir, lamivudine (Item No. 18514), and abcavir, reduces the plasma viral titer in HIV-1 infected humanized mice.²

References

- 1. Garvey, L. and Winston, A. Rilpivirine: A novel non-nucleoside reverse transcriptase inhibitor. Expert Opin. Drug Discov. 18(7), 1035-1041 (2009).
- 2. Arainga, M., Edagwa, B., Mosley, R.L., et al. A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology 14:1, (2017).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 10/03/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM